NVCT: Nuvectis Pharma Inc

NVCT新闻

• 14:32 HC Wainwright & Co. Reiterates Buy on Nuvectis Pharma, Maintains $39 Price Target
• 14:32 韦恩赖特公司重申对Nuvectis Pharma的买入评级，维持39美元的目标股价
• 12:05 Nuvectis Pharma's NXP200 BRAF Inhibitor Receives China's Breakthrough Therapy Designation
• 12:05 Nuvectis Pharma的NXP200 BRAF抑制剂获得中国突破性疗法认定
• 10:15 Nuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)
• 11:50 This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Mond
• 15:33 Nuvectis Stock Surges Around 97% in 3 Months: Here's Why
• 13:55 Wall Street Analysts Predict a 56.41% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
• 13:55 Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High?
• 15:00 PepsiCo, Delta Air Lines To Report Earnings; FOMC's Minutes Of The Meeting In Focus
• 17:15 Nuvectis: 'Hold' On NXP800 Removal And Newly Licensed Candidates (NASDAQ:NVCT)
• 16:00 What Makes Nuvectis Pharma, Inc. (NVCT) a Strong Momentum Stock: Buy Now?
• 21:20 Biotech Is The Rate Cut Trade In Disguise
• 16:00 What Makes Nuvectis Pharma (NVCT) a New Buy Stock
• 06:30 Nuvectis Pharma Jumps 20% To 52-Week High — Here's Why NVCT Stock Is Trending - Nuvectis Pharma (NASDAQ:N
• 15:12 Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Mediated Diseases and Oncology Prepared Remarks Transcript
• 13:55 Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet
• 13:55 Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade
• 12:05 Nuvectis initiates phase 1b trial combining NXP900 with osimertinib